An important international milestone reinforces the value of the solutions distributed by Euromedical: the Niti-S SPAXUS™ stent, already available in Europe, has obtained FDA 510(k) clearance in the United States.

This is a significant achievement that confirms the quality, safety, and clinical effectiveness of a technology already widely used in daily practice by numerous specialists.

An advanced solution for EUS-guided drainage

SPAXUS™ is designed to support endoscopic ultrasound (EUS)-guided drainage procedures, where precision and stability are critical factors.

Key features of the device include:

• High lumen apposition capability

• Reduced risk of migration

• Ease of deployment and safe removal

These characteristics contribute to improving the management of complex procedures, making SPAXUS™ a reliable solution for clinicians.

From European clinical practice to international recognition

The availability of the SPAXUS™ stent on the Italian market, through Euromedical, has already enabled many centers to adopt an innovative technology in the field of interventional endoscopy.

Today, FDA approval represents an authoritative confirmation of the clinical value of this solution, further strengthening confidence in its application.

Euromedical: bringing validated innovation into clinical practice

This milestone aligns with Euromedical’s mission to select and distribute advanced medical technologies, supporting healthcare professionals through:

• Technical and specialist support

• Clinical training

• Continuous education

The objective is clear: to make internationally validated solutions available locally, contributing to improved standards of care and procedural effectiveness.